THE ASSOCIATIONS OF β-ADRENORECEPTORS GENES POLYMORPHISMS WITH THE COURSE OF HEART FAILURE AND WITH THE LOW TRIIODOTHYRONINE SYNDROME (LITERATURE REVIEW AND OWN OBSERVATIONS)E

Authors

DOI:

https://doi.org/10.21856/j-PEP.2023.4.09

Keywords:

beta-adrenoreceptor, beta-blocker, heart failure, gene, low triiodothyronine syndrome, polymorphism, treatment, review

Abstract

The systematization of literature data on the associations of β-adrenoreceptors (β-AR) genes polymorphisms with the course of heart failure (HF) and with the development of low triiodothyronine syndrome (LT3S), and the results of our own study were presented. The study of associations of β-AR system genes polymorphisms  with the clinical outcome of HF and the effectiveness of β-adrenoblockers (β-AB) has been continued. It has been demonstrated that carrier state of the A allele of the Ser49Gly (c.145A > G) polymorphism of the b1-AR gene leads to a decrease in the risk of combined end point. At the same time, the carrier state of the G allele of the Gln27Glu (c.79C> G) polymorphism of the b2-AR gene increases the risk of combined end point. Administration of bisoprolol at a dose of > 5 mg leads to a reduction of the risk of the combined endpoint, provided the G/A genotype of the Ser49Gly (c.145A > G) polymorphism of the β1-AR gene is present. The use of bisoprolol at this dose also reduces the risk of re-hospitalisation and combined endpoint, provided the homozygous genotype (C/C) of the Gln27Glu (c.79C > G) polymorphism of the β2-AR gene is present. The probability of the low triiodothyronine syndrome increases with the homozygous G/G genotype of the Gln27Glu polymorphism of the β2-AR gene and in the presence of the C/T polymorphism of the Serβ75 GNβ3 gene. The genotype C/G of the Gln27Glu polymorphism of the β2-AR gene is associated with a decreased risk of LT3S.

References

Kadykova O. Probl Endokryn Patol 2016;3: 17-22. https://doi.org/10.21856/j-PEP.2016.3.02

Bonfim-Silva R, Guimarгes LO, Souza Santos J, et al. J Genet 2016;95(1): 63-69. https://doi.org/10.1007/s12041-015-0599-5

Gerald W, Dorn II, Liggett SB. Mol Pharmacol Vol 2009;76(3): 466-480. https://doi.org/10.1124/mol.109.056572

Mann DL, Bristow MR. Circulation 2005;111: 2837-2849. https://doi.org/10.1161/circulationaha.104.500546

Brodde OE. Naunyn Schmiedebergs Arch Pharmacol 2007;374: 361-372. https://doi.org/10.1007/s00210-006-0125-7

Joseph SS, Lynham JA, Grace AA, et al. Br J Pharmacol 2004;142: 51-56. https://doi.org/10.1038%2Fsj.bjp.0705753

Hata JA, Williams ML, Koch WJ. J Mol Cell Cardiol 2004;37: 11-21. https://doi.org/10.1016/j.yjmcc.2004.03.014

Mason DA, Moore JD, Green SA, Liggett SB. J Biol Chem 1999;274: 12670-12674. https://doi.org/10.1074/jbc.274.18.12670

Rochais F, Vilardaga JP, Nikolaev VO, et al. J Clin Invest 2007;117: 229-235. https://doi.org/10.1172/jci30012

Swift SM, Schwarb MR, Mihlbachler KA, Liggett SB. Am J Respir Cell Mol Biol 2007;36: 236-243. https://doi.org/10.1165/rcmb.2006-0257oc

Rathz DA, Gregory KN, Fang Y, et al. J Biol Chem 2003;278: 10784-10789. https://doi.org/10.1074/jbc.M206054200

Levin M, Marullo S, Muntaner O, et al. J Biol Chemistry 2002;277: 30429-30435. https://doi.org/10.1074/jbc.m200681200

Mialet Perez J, Rathz DA, Petrashevskaya NN, et al. Nat Med 2001;9: 1300-1305. https://doi.org/10.1038/nm930

Wagoner LE, Craft LL, Zengel P, et al. Am Heart J 2002;144: 840-846. https://doi.org/10.1067/mhj.2002.125325

Sandilands AJ, Parameshwar J, Large S, et al. Heart 2005;91: 1613-1614. https://doi.org/10.1136/hrt.2004.047282

Leineweber K, Bruck H, Temme T, et al. Pharmacogenet Genomics 2006;16: 9-13. https://doi.org/10.1097/01.fpc.0000184956.16077.93

Bruck H, Leineweber K, Temme T, et al. J Am Coll Cardiol 2005;46: 2111-2115. https://doi.org/10.1016/j.jacc.2005.08.041

Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, et al. N Engl J Med 2001;31(22): 1659-1667. https://doi.org/10.1056/nejm200105313442202

Cohn JN, Pfeffer MA, Rouleau J, et al. Eur J Heart Fail 2003;5: 659-667. https://doi.org/10.1016/s1388-9842(03)00163-6

Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. Proc Natl Acad Sci USA 2006;103: 11288-11293. https://doi.org/10.1073/pnas.0509937103

White HL, de Boer RA, Maqbool A, et al. Eur J Heart Fail 2003;5: 463-468. https://doi.org/10.1016/s1388-9842(03)00044-8

Kirstein SL, Insel PA. Pharmacol Rev 2004;56: 31-52. https://doi.org/10.1124/pr.56.1.2

Hawkins GA,Tantisira K, Meyers DA, et al. Am J Respir Crit Care Med 2006;174: 1101-1109. https://doi.org/10.1164/rccm.200509-1405oc

Drysdale CM, McGraw DW, Stack CB, et al. Proc Natl Acad Sci USA 2000;97: 10483-10488. https://doi.org/10.1073/pnas.97.19.10483

Lanfear DE, Jones PG, Marsh S. JAMA 2005;294(12): 1526-1533. https://doi.org/10.1001/jama.294.12.1526

Hesse C, Eisenach JH. Curr Pharmacogenomics Person Med 2008;6(3): 160-170. https://doi.org/10.2174/1875692110806030160

Eisenach JH, Clark ES, Charkoudian N, et al. J Appl Physiol 2002;92: 2019-2025. https://doi.org/10.1152/japplphysiol.01025.2001

Cockcroft JR, Gazis AG, Cross DJ, et al. Hypertension 2000;36: 371-375. https://doi.org/10.1161/01.hyp.36.3.371

Bruck H, Leineweber K, Park J, et al. Clin Pharmacol Ther 2005;78: 232-238. https://doi.org/10.1016/j.clpt.2005.06.002

Pojoga L, Kolatkar NS, Williams JS, et al. Hypertension 2006;48: 892-900. https://doi.org/10.1161/01.hyp.0000244688.45472.95

Heckbert SR, Hindorff LA, Edwards KL, et al. Circulation 2003;107: 2021-2024. https://doi.org/10.1161/01.cir.0000065231.07729.92

Sotoodehnia N, Siscovick DS, Vatta M, et al. Circulation 2006;113(15): 1842-1848. https://doi.org/10.1161/circulationaha.105.582833

Shin J, Lobmeyer MT, Gong Y, et al. Am J Cardiol 2007;99: 250-255. https://doi.org/10.1016/j.amjcard.2006.08.020

Iaccarino G, Izzo, Trimarco V, et al. Clin Pharmacol Ther 2006;80: 633-645. https://doi.org/10.1016/j.clpt.2006.09.006

Kaye DM, Smirk B, Williams C, et al. Pharmacogenetics 2003;13: 379-382. https://doi.org/10.1097/00008571-200307000-00002

Sheppard R, Hsich E, Damp J, et al. Circ Heart Fail 2016;9: e002683 https://doi.org/10.1161/circheartfailure.115.002683

Baumgart D, Naber C, Haude M, et al. Circ Res 1999;85: 965-969. https://doi.org/10.1161/01.res.85.10.965

Virchow S, Ansorge N, Rosskopf D, et al. Arch Pharmacol 1999;369: 27-32. https://doi.org/10.1007/s002109900040

McNamara DM, Taylor AL, Tam SW, et al. JACC Heart Fail 2014;2: 551-557. https://doi.org/10.1016/j.jchf.2014.04.016

Rosskopf D, Busch S, Manthey I, Siffert W. Hypertension 2000;36: 33-41. https://doi.org/10.1161/01.hyp.36.1.33

Casiglia E,Tikhonoff V, Boschetti G, et al. Am J Hypertens 2012;25(4): 451-457. https://doi.org/10.1038/ajh.2011.257

Chemello D, Rohde LE, Santos KG, et al. Europace 2010;12: 686-691. https://doi.org/10.1093/europace/euq040

Schmitz B, De Maria R, Gatsios D, et al. CircCardiovasc Genet 2014;7: 760-770. https://doi.org/10.1161/circgenetics.113.000384

Silva JE. Thyroid 1995;5: 481-492. https://doi.org/10.1089/thy.1995.5.481

Bencivenga L, Liccardo D, Napolitano C, et al. Heart Fail Clin 2019;15(3): 409-419. https://doi.org/10.1016/j.hfc.2019.02.009

Metaxa S, Missouris C, Mavrogianni D, et al. Curr Vasc Pharmacol 2018;16(6): 618-623. https://doi.org/10.2174/1570161115666170919180959

Pyvovar SM. Optimisation of prognosis of the clinical outcome and effectiveness of heart failure treatment inpatients with coronary artery disease with concomitant thyroid pathology, Kharkiv, 2021: 383 p.

Pyvovar SM, Rudyk YuS, Lozyk TV, et al. Ukr Ther J 2019;4: 97-105.

Covolo L, Gelatti U, Metra M, et al. Eur Heart J 2004;25: 1534-1541. https://doi.org/10.1016/j.ehj.2004.06.015

Akhter S, D'souza K, Petrashevskaya N, et al. Am J Physiol Heart Circ Physiol 2006;290: H1427-H1432. https://doi.org/10.1152/ajpheart.00908.2005

Zolk O, Kilter H, Flesch M, et al. Biochem Biophys Res Commun 1998;248: 801-805. https://doi.org/10.1006/bbrc.1998.9030

de Groote P, Helbecque N, Lamblin N, et al. Pharmacogenet Genomics 2005;15: 137-142. https://doi.org/10.1097/01213011-200503000-00001

Aquilante CL, Yarandi NH, Cavallari LH, et al. The Pharmacogenomics J 2008;8: 408-415. https://doi.org/10.1038/sj.tpj.6500490

Rathz DA, Brown KM, Kramer LA, Liggett SB. J Cardiovasc Pharmacol 2002;39: 155-160. https://doi.org/10.1097/00005344-200202000-00001

Ranade K, Jorgenson E, Sheu W, et al. Am J Hum Genet 2002;70: 935-942. https://doi.org/10.1086/339621

Metrich M, Mehmeti F, Feliciano H, et al. Plos one 2016;11(9): e0163475. https://doi.org/10.1371/journal.pone.0163475

Xiao RP. Sci STKE 2001;2001(104): re15. https://doi.org/10.1126/stke.2001.104.re15

Matkovich SJ, Van Booven DJ, Hindes A, et al. J Clin Invest 2010;120: 280-289. https://doi.org/10.1172/jci39085

Siomchenko VV, Ruban AA. Economy and Society 2018;16: 959-994.

Pyvovar SM, Rudyk YuS, Kopytsya NP, et al. Pol Med J 2019;XLVII (281): 170-176.

Pyvovar SM, Rudyk YuS, Lozyk TV, et al. Probl Med 2019;5-6(23): 30-35.

Kim B, Carvalho-Bianco K, Larsen R. Arq Bras Endocrinol Metab 2004;48(1): 171-175. https://doi.org/10.1590/s0004-27302004000100019

Xiao RP, Avdonin P, Zhou YY, et al. Circ Res 1999;84: 43-52. https://doi.org/10.1161/01.res.84.1.43

Zamah AM, Delahunty M, Luttrell LM, Lefkowitz RJ. J Biol Chem 2002;277: 31249-31256. https://doi.org/10.1074/jbc.m202753200

Chen L, Meyers D, Javorsky G, et al. Pharmacogenet Genomics 2007;17: 941-949. https://doi.org/10.1097/fpc.0b013e3282ef7354

Luo M, Bi Y, Xu YX. Chin Med J (Engl) 2007;120: 1720-1723.

Metra M, Covolo L, Pezzali N, et al. Cardiovasc Drugs 2010;24: 49-60. https://doi.org/10.1007/s10557-010-6220-5

Terra SG, Hamilton KK, Pauly DF, et al. Pharmacogenet Genomics 2005;15: 227-234. https://doi.org/10.1097/01213011-200504000-00006

Yu WP, Lou M, Deng B, et al. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34: 776-780.

Rienstra M, Damman K, Mulder BA, et al. JACC Heart Fail 2013;1: 21-28. https://doi.org/10.1016/j.jchf.2012.09.002

Pyvovar SM, Rudyk YuS, Isaeva AS, et al. Georgian Medical News 2019;10(295): 76-84.

Terra SG, Pauly DF, Lee CR, et al. Clin Pharmacol Ther 2005;77(3): 127-137. https://doi.org/10.1016/j.clpt.2004.10.006

Pacanowski AM, Johnson JA. Pharmacological Rev 2007;59(1): 2-4. https://doi.org/10.1124/pr.59.1.6

Petersen M, Andersen JT, Hjelvang BR, et al. Br J Clin Pharmacol 2011;71(4): 556-565. https://doi.org/10.1111/j.1365-2125.2010.03868.x

Nguyen MN, Kiriazis H, Ruggiero D, et al. Am J Physiol Heart Circ Physiol 2015;309(5): H946-H957. https://doi.org/10.1152/ajpheart.00405.2015

Downloads

Published

2023-12-15

How to Cite

Pyvovar, S., Rudyk, I., & Shcherban, T. (2023). THE ASSOCIATIONS OF β-ADRENORECEPTORS GENES POLYMORPHISMS WITH THE COURSE OF HEART FAILURE AND WITH THE LOW TRIIODOTHYRONINE SYNDROME (LITERATURE REVIEW AND OWN OBSERVATIONS)E . Problems of Endocrine Pathology, 80(4), 77–94. https://doi.org/10.21856/j-PEP.2023.4.09

Similar Articles

1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.